Please login to the form below
New coronavirus sees drug developers scramble to develop a vaccine
Researchers work to combat emerging threat
Sanofi completes acquisition of immuno-oncology specialist Synthorx
Synthorx is now fully owned by the French drugmaker
Roche's checkpoint inhibitor fails pivotal urothelial cancer trial
Phase 3 trial shows no effect on disease-free survival and misses its primary endpoint
Epizyme wins FDA approval for epithelioid sarcoma treatment
Phase 2 clinical trial shows response rates outweigh risks
QiC Dermatology is now open for entry
Supported by The British Skin Foundation, The Primary Care Dermatology Society
UK biotech funding falls 40% between 2018 and 2019
Drop attributed to global uncertainty and Neil Woodford scandal
AZ’s Imfinzi scores orphan drug status in liver cancer
Company is looking to gain approval in the first-line advanced setting
FDA approves Horizon's thyroid eye disease drug ahead of schedule
First FDA-approved treatment for rare autoimmune condition
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price
Vowed to break patent if company goes ahead with proposed price
Q&A: Emma Sergeant
PME interviews president of the DAS Group of Companies in Europe
-
Q&A: Vicky BramhamPME interviews OPEN Health Patient & Brand Communications' managing director, PR
-
Q&A: Steve ClarkPME interviews the director of Redwood Brand Curators
-
EU group calls for 'targeted actions' to mitigate impact of BrexitCommittee wants to ensure safe supply of drugs and medical devices
-
UPDATED: J&J's $8bn Risperdal judgment reduced to $6.8mCompany will still appeal reduced verdict
-
FDA fast-tracks GSK’s anti-BCMA drug for multiple myelomaIf approved will become first BCMA targeting drug for myeloma
-
EU grants conditional approval to Roche's lymphoma drug PolivyDrug demonstrated a 40% complete response rate in trial
-
Novartis gets EU approval for multiple sclerosis therapy MayzentOffers subgroup of patients an important new treatment option
-
J&J wins another label expansion for Darzalex in Europe
Multiple myeloma treatment indicated for early use
-
Immuno-oncology, personalised medicine continues to drive pharma sectorNew GlobalData survey identifies key trends impacting the industry
Latest appointments
-
Lucid Group names Neil Flash chief commercial officerFlash joins the team from dna Communications
-
New hires at bluebird bio, BioNTech and Provention BioThe latest movers in pharma
-
IGNIFI expands healthcare team with two new hiresCraig Lambert and Rebecca Dargue join the team
-
Christie Anbar appointed global healthcare lead at Ruder FinnAnbar will oversee the agency's entire healthcare business
-
RFA strengthens team with a host of hires and promotions New hires coincide with continued growth
Featured jobs
-
Consultant
-
competitive salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Vice President
-
Competitive Salary Offered
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director or Senior Account Director
-
Salary TBC
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
Subscribe to our email news alerts
- FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma
- Lilly will aim for one $1bn-$5bn deal per quarter in 2020
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- Immuno-oncology, personalised medicine continues to drive pharma sector
- FDA delays decision on Intercept's NASH drug by three months
- Roche’s SMA treatment risdiplam hits another clinical target
- New coronavirus sees drug developers scramble to develop a vaccine
- Sanofi completes acquisition of immuno-oncology specialist Synthorx
- Roche's checkpoint inhibitor fails pivotal urothelial cancer trial
- Epizyme wins FDA approval for epithelioid sarcoma treatment
- Pharma Brand Planners' Blog (Part 8)
- Happy Chinese New Year 2020 - The Year of The Rat
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Happy Chinese New Year 2020 - The Year of The Rat
- A fond farewell to The Year of the Pig...
- White Paper for download - Explaining the price of your product
- In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
- OPEN Health expands offering with the launch of a new Learning & Development specialist team
- Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Quick links
Infographics
